Latest Industry Insights
Industry Insight
“I’ve Never Seen Anything as Effective”: Exploring the Combination of Psychedelics and Psychotherapy
While most psychedelic drugs remain illegal in the United States, ketamine has been legal for use by registered practitioners since the 1960s. With the recent recognition of the compound’s use as an antidepressant, more and more clinics are rolling out ketamine-assisted psychotherapy programs.
Industry Insight
Can Psilocybin Help Smokers Quit? This Clinical Trial Aims to Find Out
Psilocybin – the primary active ingredient in magic mushrooms – is to be studied in a new clinical trial that will test whether the psychedelic compound can help people quit smoking.
Industry Insight
Early Detection of Brain Tumors and Beyond
The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm3 from a blood sample in as little as fifteen minutes.
Industry Insight
MDMA for Traumatic Brain Injury To Be Studied in $1.5 Million Partnership
A new partnership between MAPS Public Benefit Corp (PBC) and Wesana Health will see $1.5 million contributed towards investigation into the therapeutic potential of the psychedelic compound MDMA in treating traumatic brain injury (TBI).
Industry Insight
How Can AI Techniques Improve How We Diagnose Dementia?
Developing treatments for dementia remains one of the most forbidding challenges facing neurology. Traditionally, paper-based assessments are used by clinicians to diagnose patients. But London-based company Cognetivity says that its AI-based platform could improve diagnostics. We spoke with the company’s co-founder and chief science officer, Dr. Seyed Khaligh-Razavi, to find out more.
Industry Insight
How Can We Make It Easier To Implant a Brain-Computer Interface?
Brain-computer interfaces (BCI) have the potential to revolutionize the lives of people with severe motor and nervous system impairments. But users of current BCI technology must face the hurdle of implanting the device in their brain. We spoke to Professor Florian Solzbacher, co-founder and chairman of Blackrock, to find out more about how neurotechnology companies are overcoming this obstacle.
Industry Insight
Accelerating Biological Discovery With Open-Source Spatial Genomics Data
In this interview, Dr. George Emanuel discusses some of the most exciting findings from the Mouse Receptor Map and highlights how the datasets will benefit the Human Cell Atlas project.
Industry Insight
Revolutionizing the Science of Nerve Repair and Regeneration
To learn more about the causes and consequences of peripheral nerve damage and some of the solutions available to patients, Technology Networks spoke with Karen Zaderej, chief executive officer of Axogen.
Industry Insight
The Value of Investing in Sex- and Gender-Based Alzheimer’s Disease Research
Women’s Health Access Matters recently released The WHAM Report, outlining new research conducted by the RAND Corporation to study the impact of accelerating sex- and gender-based AD, heart and autoimmune research on women, their families and the economy. To learn more about the report, the recently released AD findings and their significance, we spoke to Carolee Lee, founder and CEO of WHAM.
Advertisement